Collectively, these two studies concur on a role for NF-κB expression in prostate cancer clinical behaviour and the current one suggests that the nuclear (activated) form of p65 is the one that is specifically linked with a higher likelihood of relapse. Here, NFKB1 is linked to prostate carcinoma.